The effects of weight on adverse event reporting in Parkinson's disease patients treated with IPX066 extended-release carbidopa-levodopa capsules

被引：0
|
作者：
Kell, S.
O'Connell, M.
Hsu, A.
Silver, D.
Elmer, L.
Gupta, S.
机构：
来源：
MOVEMENT DISORDERS | 2013年 / 28卷
关键词：
D O I：
暂无
中图分类号：
R74 [神经病学与精神病学];
学科分类号：
摘要：
410
引用
收藏
页码：S146 / S147
页数：2
相关论文
共 50 条
  • [41] How to Dose Extended-release Carbidopa-levodopa Capsules (IPX203) In Parkinson's Disease Patients: Experience from the Phase 3 Clinical Trial
    Hauser, R.
    Banisadr, G.
    Fisher, S.
    Visser, H.
    D'Souza, R.
    MOVEMENT DISORDERS, 2023, 38 : S27 - S28
  • [42] Comparison of single-dose motor effects of IPX066 to immediate-release carbidopa-levodopa plus entacapone (CLE) in advanced Parkinson's disease (PD) patients
    Ellenbogen, A.
    Stocchi, F.
    Duker, A. P.
    Hsu, A.
    Khanna, S.
    Modi, N.
    Rubens, R.
    Gupta, S.
    MOVEMENT DISORDERS, 2012, 27 : S115 - S116
  • [43] Conversion of advanced Parkinson's disease patients to IPX066, modified-release levodopa-carbidopa (NUMIENT™), from other levodopa-carbidopa formulations
    Gupta, S.
    Rubens, R.
    Rustay, N.
    Khanna, S.
    Kell, S.
    EUROPEAN JOURNAL OF NEUROLOGY, 2016, 23 : 526 - 526
  • [44] Comparison of IPX066, a Novel Carbidopa-Levodopa (CD-LD) Extended-Release Formulation, and CD-LD-Entacapone (CLE) in Advanced Parkinson's Disease (ASCEND-PD Trial)
    Stocchi, Fabrizio
    Dillmann, Ulrich
    Ellenbogen, Aaron
    Hsu, Ann
    Khanna, Sarita
    Rubens, Robert
    Liang, Grace
    Gupta, Suneel
    NEUROLOGY, 2012, 78
  • [45] Onset and duration of effect of extended-release carbidopa-levodopa in advanced Parkinson's disease
    Hauser, Robert A.
    Ellenbogen, Aaron
    Khanna, Sarita
    Gupta, Suneel
    Modi, Nishit B.
    NEUROPSYCHIATRIC DISEASE AND TREATMENT, 2018, 14 : 839 - 845
  • [46] Efficacy of IPX066, modified-release levodopa-carbidopa (NUMIENT™) in patients with advanced Parkinson's disease: responder analyses
    Gupta, S.
    Khanna, S.
    Rustay, N.
    Rubens, R.
    Kell, S.
    EUROPEAN JOURNAL OF NEUROLOGY, 2016, 23 : 527 - 527
  • [47] Comparison of IPX066, a novel investigational carbidopa-levodopa (CD-LD) extended-release formulation, and CD-LD-entacapone (CLE) in advanced Parkinson's disease (ASCEND-PD trial)
    Stocchi, F.
    Dillmann, U.
    Mahler, A.
    Ellenbogen, A.
    Liang, G.
    Hsu, A.
    Khanna, S.
    Rubens, R.
    Gupta, S.
    MOVEMENT DISORDERS, 2012, 27 : S140 - S140
  • [48] Open-label comparison of IPX066, a novel investigational carbidopa-levodopa (CD-LD) extended-release formulation, and controlled-release CD-LD (CR) in Parkinson's disease patients with motor fluctuation
    Tetrud, J.
    Liang, G.
    Nausieda, P.
    Hsu, A.
    O'Connell, M.
    Khanna, S.
    Kell, S.
    Ellenbogen, A.
    Tanner, C. M.
    Gupta, S.
    MOVEMENT DISORDERS, 2014, 29 : S269 - S270
  • [49] Long-Term Treatment with Extended-Release Carbidopa–Levodopa (IPX066) in Early and Advanced Parkinson’s Disease: A 9-Month Open-Label Extension Trial
    Cheryl H. Waters
    Paul Nausieda
    Lyudmila Dzyak
    Joerg Spiegel
    Monika Rudzinska
    Dee E. Silver
    Elena S. Tsurkalenko
    Sherron Kell
    Ann Hsu
    Sarita Khanna
    Suneel Gupta
    CNS Drugs, 2015, 29 : 341 - 350
  • [50] PATIENT SELF-ASSESSMENTS IN ADVANCED PARKINSON'S DISEASE WITHIN UPDRS AND "OFF" TIME SUBGROUPS: COMPARISON OF IPX066 WITH IMEDIATE-RELEASE CARBIDOPA-LEVODOPA
    Rubens, R.
    Rustay, N. R.
    Khanna, S.
    Kell, S.
    Gupta, S.
    VALUE IN HEALTH, 2015, 18 (03) : A279 - A279
12345